



(51) International Patent Classification:

C07D 295/192 (2006.01) **A61P 25/18** (2006.01)
A61K 31/495 (2006.01) **A61P 25/28** (2006.01)
A61P 25/00 (2006.01)

(21) International Application Number:

PCT/SE2011/050170

(22) International Filing Date:

17 February 2011 (17.02.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/305,581 18 February 2010 (18.02.2010) US

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **COLLINS, Craig D.** [US/US]; c/o AstraZeneca Intellectual Property, AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; AstraZeneca AB, SE-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: SOLID FORMS COMPRISING A CYCLOPROPYL AMIDE DERIVATIVE

FIG. 1



(57) Abstract: This disclosure relates to at least one solid form of 4-{(1S, 2S)-2-[(R)-4-cyclobutyl-2-methylpiperazin-1-yl]carbonyl}-cyclopropyl}-benzamide. This disclosure also relates to at least one pharmaceutical composition comprising at least one solid form described herein, methods of using the solid forms and pharmaceutical compositions comprised thereof, and processes of manufacturing the solid forms.